Event-Driven Stocks

Black Diamond Therapeutics, Inc.

BDTXNasdaq

Healthcare · Biological Products, (No Diagnostic Substances) · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 5 good● 1 severedetails ↓

Financials

SEC XBRL · annual
 FY25FY24FY23FY22FY21FY20
Revenue$70.0M$0———$0
Operating income$12.5M−$78.8M−$86.5M−$92.8M−$126.9M−$69.6M
Net income$22.4M−$69.7M−$82.4M−$91.2M−$125.6M−$67.3M
Total assets$143.0M$122.6M$158.6M$156.3M$247.7M$329.7M
Total liabilities$30.8M$39.4M$41.8M$40.6M$51.8M$21.9M
Equity$112.2M$83.3M$116.7M$115.7M$195.9M$307.8M
EPS (diluted)$0.39$-1.27$-1.88$-2.52$-3.47$-2.05
Shares out.56.7M51.7M36.5M36.3M36.1M35.9M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2025
Operating margin
17.9%
Net margin
32.0%
Return on equity
19.9%
Return on assets
15.6%
Return on capital (ROCE)
9.8%
Liabilities / assets
21.5%
Debt / equity
0.27×
Book value / share
$1.98
Revenue growth (YoY)
—
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2025
Altman Z″ (distress)
-0.83distress
Accruals / assets
−5.1%clean
Piotroski F-Score
7/8strong

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
77
/ 100
Profitability 100Growth n/aCatalyst 33Earnings quality 100Financial strength 75

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 1 severe● 5 good
  • Altman Z″ in the distress zone
  • Operating margin is positive
  • Strong return on equity (>15%)
  • Conservative leverage (liabilities < 50% of assets)
  • Positive operating cash flow
  • Clean earnings (low accruals)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Clinical trials

ClinicalTrials.gov · ongoing · next readout first

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
May 15, 20265.3M5.5+17.6%
Apr 30, 20264.5M5.3-18.2%
Apr 15, 20265.5M6.7+8.0%
Mar 31, 20265.1M10.4+0.2%
Mar 13, 20265.1M6.5+9.4%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (1)

Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.